Knowledge mapping of therapeutic cancer vaccine from 2013 to 2022: A bibliometric and visual analysis

Hum Vaccin Immunother. 2023 Aug;19(2):2254262. doi: 10.1080/21645515.2023.2254262. Epub 2023 Sep 20.

Abstract

The investigation of therapeutic cancer vaccines has been ongoing for the past century. Herein, we used VOSviewer and CiteSpace to perform the first global bibliometric analysis of the literature on therapeutic cancer vaccines from 2013 to 2022 aiming to explore the current status and potential research trends. The findings revealed a consistent upward trend in both publication counts and citations. The United States emerged as the leading contributor with the highest number of published papers. Additionally, the analysis of references and keywords indicated that therapeutic cancer vaccines have long been popular topics, whereas neoantigen vaccines, mRNA vaccines, combination strategies, and vaccine delivery systems are emerging research hotspots. This bibliometric study provides a comprehensive and important overview of the current knowledge and potential developments in therapeutic cancer vaccines from 2013 to 2022, which may serve as a valuable reference for scholars interested in further exploring this promising field.

Keywords: Citespace; Therapeutic cancer vaccine; VOSviewer; bibliometric analysis; immunotherapy; knowledge map.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bibliometrics
  • Cancer Vaccines*
  • Humans
  • Neoplasms* / therapy
  • mRNA Vaccines

Substances

  • Cancer Vaccines
  • mRNA Vaccines

Grants and funding

This work was supported by the Major International (Regional) Joint Research Program of the National Natural Science Foundation of China [No. 81920108027], Chongqing Outstanding Youth Science Fundation [No. cstc2020jcyj-jqX0030], and Chongqing Science and Technology Innovation Leading Talent Support Program [No. cstc2021ycjh-bgzxm0073], Funding for Chongqing University Innovation Research Group, and Funding for Chongqing Young and Middle-Aged Medical Excellence Team.